Company news
Omeros Corporation news in 2026
Omeros Corporation's news releases, calls and decks from 2026, newest first.
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
October 16, 2026
Omeros Corporation Reports Second Quarter 2026 Financial Results
August 12, 2026
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
August 10, 2026
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
August 3, 2026
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
June 26, 2026
Omeros Corporation Reports First Quarter 2026 Financial Results
May 13, 2026
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
May 11, 2026
Omeros Corporation - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA
April 17, 2026
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
April 16, 2026
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
March 30, 2026
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
March 26, 2026
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
March 21, 2026
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
February 16, 2026
Omeros Announces First Commercial Sales of YARTEMLEA®
January 27, 2026